It takes a Village

Dr. Marcel van Duin is Chief Scientific Officer and responsible for External Innovation and Emerging Science at Organon, a company with the vision to advance the health of women.
Marcel was previously Vice President, Head of R&D Alliances for Reproductive Medicine and Maternal Health (RM&MH) and Therapeutic Area Head for Research in RM&MH at Ferring Pharmaceuticals and member of the global drug discovery leadership team. Key scientific focus was on projects for Endometriosis, Infertility and Obstetrical complications such as preterm labor and preeclampsia as well as a strong outreach to external opportunities.
Before that his career spanned leadership R&D responsibilities in multiple Women’s Health areas in Merck & Co, Schering Plough and Organon where he started his professional journey in the pharmaceutical industry in Oss, the Netherlands.
Marcel holds a B.S. in biology from Utrecht university and PhD at Erasmus university, Rotterdam, both in the Netherlands.
At present he holds an honorary professorship in Innovation at the Chinese Academy of Sciences in Beijing, China. He has (co-)authored over 60 scientific publications.

Dr. Pronovost is a world-renowned patient safety champion, innovator, critical care physician, researcher (publishing over 1000 peer review publications), entrepreneur (founding two health care startups that were acquired), and a global thought leader, informing US and global health policy. His scientific work leveraging checklists to reduce catheter-related bloodstream infections has saved thousands of lives and earned him high-profile accolades, including being named one of the 100 most influential people in the world by Time Magazine, receiving a coveted MacArthur Foundation “genius grant” in 2008.

Dr. Pronovost currently serves as University Health’s Chief Quality & Clinical Transformation Officer, a role in which he is charged with fostering ideation and implementation for new protocols to eliminate defects in value and thereby enhance quality of care. Previously, Dr. Pronovost served as the Senior Vice President for Patient Safety and Quality at Johns Hopkins Medicine as well as the founder and director of the Johns Hopkins Medicine Armstrong Institute for Patient Safety and Quality. In this role, he worked to eliminate all harms in one health system following on his success in eliminating one harm in most health systems across the U.S. Dr. Pronovost also served as the Senior Vice President for Clinical Strategy and the Chief Medical officer for UnitedHealthcare.

Brad Fluegel was most recently the senior vice president – chief healthcare commercial market development officer for Walgreen Co., based in Deerfield, Ill. Previously, he was Chief Strategy and Business Development officer for Walgreens, responsible for corporate strategy and business development.

He joined Walgreens in October 2012 after previously serving as executive in residence at Health Evolution Partners. Before that he was executive vice president and chief strategy and external affairs officer of Wellpoint (now Anthem), among the nation’s largest health benefits companies.

Prior to Wellpoint, Brad was senior vice president of national accounts and vice president, enterprise strategy at Aetna, Inc. In this role, he led the national accounts business and was responsible for developing and executing on strategies that expanded Aetna’s position as a leader in the large employer market.

Earlier, Brad was CEO for Reden & Anders (Optum Consulting) and health sector leader at Tillinghast-Towers Perrin, a clinical, actuarial and management consulting practice that served all sectors of the health care industry.

Brad currently serves on the Board of Directors of MJHS Health System in New York City, Performant Financial Corporation, Premera Blue Cross, Itamar Medical and AdhereHealth. He also advises several health care companies and private equity firms.  He served on the Fitbit Board of Directors until its sale to Google in early 2021 and Alight Solutions until it’s merger in July of 2021.

Brad earned a master’s degree in public policy from Harvard University’s Kennedy School of Government and a bachelor of arts in business administration from the University of Washington. He also serves as a lecturer at the University of Pennsylvania’s Wharton School of Business.

With a distinguished career in health care spanning more than thirty years, Jim is a Founder and Managing Partner of Tyree & D’Angelo Partners (TDP), a private equity firm focused on investments in promising, underperforming businesses in the lower-middle market.

Prior to founding TDP in 2012, Jim had an outstanding 15 year career at Abbott, holding executive positions in its pharmaceutical and nutrition businesses. Jim was involved in many of the company’s major acquisitions and was responsible for the restructuring of TAP, Abbott’s joint venture with Takeda Chemicals of Japan. Jim served as Executive Vice President, Pharmaceutical Products, Abbott’s largest business, and was also directly responsible for establishing and managing Abbott Global Nutrition, Abbott’s second largest operating division. Jim also served as President of Abbott Biotech Ventures. Prior to his career at Abbott, Jim was President of Sugen, Inc., a biotech company focused on oncology, and held management positions at Bristol-Myers Squibb and Pfizer.

Jim currently serves or has served as an independent director of a number of privately and publicly held companies. He is also a member of The Council of Advisors at the University of Chicago Graduate School of Business (Booth). He earned his MBA from the Kelley School of Business at Indiana University, as well as two bachelor degrees in psychology and forensic studies from Indiana University.

Adrienne is a retired American Airlines executive with over 20 years of corporate benefits, operations, and human resources experience.  During her career, she has developed deep expertise in identifying organizational needs matched with practical solutions. This experience includes evaluating hundreds of health care and health care technology companies and their ability to meet complex demands in a constantly evolving landscape.  She created an innovative, best-in-class ecosystem of health care and benefits programs for 100,000 employees of the world’s largest airline. She was accountable for oversight of challenging integrations from ideation through to execution.

She is the founder and CEO of The Camille Group, a strategic consulting firm.  Through her experience with working with sophisticated stakeholders in health care and employee benefits, her firm offers evidence-based solutions tailored to client needs.  The firm’s personalized and collaborative approach helps clients identify opportunities for revenue growth, strategies for effective operational execution, and provides ongoing advisory services to help ensure sustained success.

George Keefe served as SVP of Market Access and SVP of External Affairs and Public Policy during his 20 year career with Teva Pharmaceuticals. His leadership roles included Market Access, Government Affairs, Public Policy, Payer Marketing, Pricing and Contracting, Reimbursement Strategies, Patient Assistance and Medical Affairs. George served on Teva’s US and North America leadership teams from 2015 through 2021.

George joined Teva in 2002 where he took on various positions of increasing responsibility, assuming leadership of U.S. Market Access in 2015. George was involved with launching and commercializing dozens of products covering numerous therapeutic areas and digital health. In his most recent role, George led the Government Affairs, Public Policy and Medical Affairs functions. He helped to guide Teva’s advocacy efforts and represented Teva’s interests on a range of key issues. George worked with Congressional leaders, Members of Congress, key Administration officials and other policymakers on issues of critical importance to the industry.

George holds a Bachelor of Arts degree in Economics with a minor in Political Science from SUNY Geneseo and an MBA in Finance and Marketing from the University at Buffalo. He lives in Santa Rosa Beach, Florida with his wife Linda. George enjoys hiking, cycling, playing basketball and reading historical biographies of world leaders.

A medical device industry veteran with more than 25 years experience, Chip is currently founder and CEO of Regatta Medical, focusing on acquiring companies and assets in the products and services areas of the medical device industry.

Chip previously served as CEO of Creganna Medical, a leading Ireland-based supplier to the minimally invasive medical device industry. After a successful three year effort to focus the company on higher growth markets and improve operational performance, Creganna Medical was sold to TE Connectivity in 2016. Preceding Creganna, Chip was an Entrepreneur-in-Residence within the FDA at CDRH in 2012-13. He co-led the Innovation Pathway team focused on streamlining aspects of medical device clinical trials in the U.S.  Prior to his work at FDA, Chip had a long and distinguished career at Abbott, including President of Abbott Vascular, Abbott’s cardiovascular device division, where he led the organization from a small vessel closure business through acquisitions and organic growth to global leadership in the drug-eluting stent market with the launch of Xience in the U.S., Japan, and China. Abbott Vascular became a multi-billion dollar division of Abbott.

Chip earned a bachelor’s degree in Chemical Engineering from the Massachusetts Institute of Technology and a master’s degree in Business Administration from Harvard Business School.

Tom consults to health systems, independent providers, payors, private equity firms and others on value-based care, pharmacy cost management, and patient engagement. Mr. Davis recently finished an assignment as Senior Vice President at Somatus, a managed kidney care company. He has also served as Market President for JenCare/ChenMed in Atlanta, a capitated medical practice serving low-income Medicare Advantage patients.

For 16 years Tom served as Senior Vice President at Coventry Health Care running health plans, pharmacy programs, product development, digital engagement, and product development. In 2013 the company was sold to Aetna.

Mr. Davis has also held leadership positions with United Healthcare, MetraHealth, and Prudential Health Care System. Earlier in his career he worked in management consulting and private equity investing at APM and E.M. Warburg Pincus. Mr. Davis holds an MBA from the Wharton School and a BA in Religion from Wesleyan University. He lives in Atlanta, Georgia.

Josh is a health care product, operations and strategy leader with a 20-year track record of successfully creating, bringing to market, and selling employer-, payer- and provider-facing products at industry-leading healthcare companies. Josh’s areas of expertise include Medicare, telehealth, post-acute care, employer group benefits, complex disease management, product development and management, and finance.

Josh holds a BS in Nutritional Science from Cornell University and an MBA in Finance and Investments from the Zicklin School of Business (Baruch College, City University of New York)

A dynamic C-suite commercialization executive and proven CEO, leading 6 diverse B2B and B2C businesses to record growth and profit in both public and private companies, ranging from start up to $1 billion in revenue. Industry experience includes healthcare, consumer products, retail via direct to consumer and wholesale channels, and media. An innovative leader consistently able to drive growth in start up environments as well as large, matrixed organizations. Strong track record of attracting and retaining top talent to develop results-driven executive teams.

Exceptional communicator who formulates highly resonant messaging resulting in scaled adoption of new products, services, technologies, and business models. Deep expertise and a novel approach to building impactful strategic alliances of scale across key stakeholder groups and industry sectors, most recently with healthcare Key Opinion Leaders from hospital systems, academic medical institutions, physician chairs, government agencies, employer networks, patient advocacy groups, professional organizations, government and commercial payers, financial institutions, and biotech service providers.

Current member of 8 boards and councils, primarily focused on digital health, biotechnology, and ESG, including Laguna Health, Springboard Enterprise Life Sciences Council, The United Nations Development Programme, MIT ReACT, and Harvard Women’s Leadership Board.

Pamela Gill is a healthcare and not-for-profit consultant who brings experience as a clinical provider who has served in multiple executive positions, most recently as the President and CEO of Recovery Resources, a comprehensive non-profit behavioral health care organization where she led the acquisition of the agency by a major academic medical Center. Pam has had an extensive career in hospital and healthcare administration including leadership positions at The Cleveland Clinic, a global healthcare organization. Pam is a registered nurse; her clinical background is in neurosciences and her areas of interest are strategic planning and population health management. Pam has keen interest in innovative solutions through both technology, business partnerships and systems organization. Pam’s career has included strategic experience in multiple health system mergers and acquisitions

A Cleveland, Ohio native, she holds a nursing degree, a bachelor’s degree in Health Care Administration and a master’s degree in biomedical ethics. She is passionate about the arts and community development serving on multiple boards.

Kirk Keaffaber leads Digital Health for the Biomedicines Division covering neurosciences and immunology. In this role, he has led the digital health strategy for the business unit, the first digital product to market from concept to commercialization, digital-first components of customer support, contributed to clinical digital health efforts, and established external collaborations for innovation. Prior to that he was Senior Director responsible for Commercial Strategy & Operations in Neurosciences, which included traditional activities, but also creating a digital health focus within the business unit. Prior to that, he led Integrated/Omni-Channel Marketing, building from a single brand to then become a large COE across all brands and business units for the US market. In his 21 years at Lilly, Kirk has held other leadership positions in global brand marketing, US customer marketing, and US Sales across many therapeutic areas, and also roles developing new commercial innovation.

Mr. Oldroyd has spent over 26 years in the healthcare industry.  His primary focus has been on startup organizations, building and executing business development and commercial strategies for new assets in therapeutics, diagnostics, real world data/AI engineering and software.  His expertise involves finding the best business use cases to generate revenue for new products in a large and challenging healthcare ecosystem.  He is currently the Chief Business Officer at C2i Genomics and sits on the Board of Directors at Base 10 Genetics.  Additionally, Mr. Oldroyd consults or advises a number of startup and larger organizations within the digital health, data security and diagnostic industries.  His education includes a Juris Doctor with a specialty in health law and policy.  Mr. Oldroyd spends much of his free time with his five adult children and two grandsons.  His other interests include aviation, as a private pilot, and adventure motorcycling.

Yael leads the Nutrino Health business as part of Medtronic Diabetes. As CEO of Nutrino, she led the company to early revenue and successful acquisition in 2018. Previously, Yael held multiple commercial roles: VP of Business Development at Sensible Medical, VP Marketing at American Well, and Director care management marketing at TriZetto (acquired by Cognizant). Yael holds a BA in psychology from Hebrew University and an MBA from MIT Sloan School of Management.

Moran Shochat-Snir leads the Emerging platforms and Data teams at Invitae (NVTA), a leading genetics company whose mission is to bring comprehensive genetic information into mainstream medicine. Moran is the co-founder and former CEO of Clear Genetics, which was acquired by Invitae in November 2019. Clear Genetics developed software to thoughtfully scale delivery of genetic services and integrate it into routine patient care. Prior, Moran was at Medtronic, where she held several key roles, including leading business strategy, portfolio prioritization, and business development. She was also the co-founder of MorNetware, an Israeli software company that scales delivery of prenatal carrier screening. Moran was an officer in Israel Defense Forces’ Elite software unit, then studied Biomedical Engineering at Tel Aviv University for her Bachelors and Masters Degrees. She has an MBA from the Wharton Business School and is a Y combinator Alum.

Dr. Avi Tsur, M.D is the Founder and Director of the Sheba Women’s Health Innovation Center, a collaborative effort or ARC, the Sheba Department of Obstetrics & Gynecology and the Gertner Institute for Health Policy and Epidemiology.

Serves as Head of the Sheba Beyond Women’s Health Telemedicine Services providing cutting edge remote healthcare services across Israel and Beyond.

Clinically trained in the Hadassah Medical School, Sheba Medical Center and Stanford University Medical Center, and clinically serves as attending physician at the Sheba Antepartum (high-risk pregnancy) Department, High-risk Pregnancy Clinics and the Obstetrics and Gynecology Ultrasound Unit.

Leading a National Ministry of Health Committee, promoting telemedicine in women’s healthcare.

Dr. Tsur holds patents for several predictive machine learning models in the field of Obstetrics and Gynecology, is the founder of BirthAI.org and was the lead medical inventor of the Lioness, a mechanical device for prevention of preterm birth currently commercialized by Pregnantech.

Serves as principal investigator of several cutting edge studies –  PTBiome, precision gestational diabetes, and remote postdate fetal monitoring.  Author of 35 peer reviewed manuscripts and three book chapters.

Mentor at Biodesign Israel and the and at the Interdisciplinary Center Herzliya (IDC) program in Healthcare Innovation.

Michael is an experienced telehealth entrepreneur, executive and advisor focused on combining emerging technology and business model innovation to commercialize and scale behavioral and population healthcare solutions. Over the past decade, he has raised over $30M from highly regarded venture funds – including .406 Ventures, Sandbox/BCBS Ventures, HLM, Canaan Partners and AXA Strategic Ventures – to start and grow two, technology-enabled healthcare services companies, Annum Health and AbleTo. In 2020, AbleTo was acquired by the nation’s largest health plan.

Currently, Michael serves as a board director at City Health Works (chairman), Medorion, wayForward, Wellth, and Project Health Minds (not for profit.) He is also an advisor to Intellihealth, Iris OB Health, CareTribe, Equip BH, and EMK Capital, a UK PE firm. Previously, he was an Entrepreneur-In-Residence (EIR) at Weill Cornell Medicine and has served on the board of Visiting Nurse Services of New York (2010-15). Prior to his entrepreneurial career, Michael worked at Furman Selz (investment banking), Bertelsmann, and McKinsey & Co.

Michael wrote Landing on the right Side of Your Ass, A Survival Guide for the Recently Unemployed (Three Rivers Press / Random House) and the “Hiring Line” columnist for BusinessWeek. He has a BA in political science from University of Chicago and an MBA from Harvard Business School. He lives with his wife in New York.

Uzi is a serial entrepreneur, longtime business executive and sales leader in the worlds of medical devices and digital health. After serving at multiple companies as a sales and marketing executive, Uzi managed Medcon, a leader in cardiology informatics, and was in charge of its growth from inception to a category leader, IPO, and sale to McKesson. At McKesson, Uzi acted as the VP cardiology.  Today, Uzi is the chief commercial officer for Tyto Care, a leading digital health startup in the field of remote patient monitoring. Uzi holds a BSC in computer science and mathematics MA in conflict resolution and MBA from Tel Aviv University.

Venture Capitalist and Investment Banker, Ran Reske has turned his decades of experience steering hyper-growth businesses into building his own enterprise with Resident, a house of digitally-native brands that includes Nectar, DreamCloud, Level, Awara, Wovenly and Bundle. Under Ran’s dynamic leadership, the company boasted nearly $250 million in gross sales in 2018, its second year in business.

Alongside co-CEO Eric Hutchinson, Ran oversees all aspects of the business with a deliberate concentration on operational efficiency, strategic partnerships, manufacturing, and customer service to accelerate the company’s overall growth trajectory. As Resident continues to expand its portfolio of brands across the home goods category, he is laser-focused on talent acquisition and building a highly productive, diversified workforce that now includes 250 employees, and counting, across 5 countries and 15 cities.

Prior to launching Resident, Ran led early to late-stage venture investments with Norwest Venture Partners, where he focused on companies in e-commerce, media and mobile. He has also spearheaded corporate development divisions of both Amdocs and Pamplona Capital Management, and held roles in the investment banking division of Citigroup. In that role, Ran focused efforts on strategic advisory assignments for transactions like M-Systems’ $1.3 billion acquisition and Cellcom’s $400 million IPO.

Born in Israel and raised in Kenya, Ran takes pride in being a global citizen who currently resides in San Francisco with his wife and two sons.

Roy is a tech entrepreneur and pioneer of online optical since he founded EyeBuyDirect in 2005. By partnering with the Essilor Group (EPA:EI) in 2012, Roy led the rollup of the optical industry’s largest ecommerce companies, and was the group’s President and CEO. With over 1000 employees and operations in over 10 countries, Roy led the world’s largest online optical group that continues to provide access to product and education to vision consumers worldwide. Roy sold his company to Essilor International in January 2018.

Roy was recognized by the World Economic Forum as a Young Global Leader of 2016. He is an alumnus of the Harvard Business School.